Northeast Pharmaceutical announced that it has received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice issued by the National Medical Products Administration, approving the registration of baloxavir marboxil active pharmaceutical ingredient. The drug is an anti-influenza virus medication indicated for adult and pediatric influenza patients. This approval will help enrich the company's product pipeline and enhance market competitiveness, but the timing of production and sales as well as specific sales conditions remain uncertain.
Northeast Pharmaceutical Group Co LtdApproval of baloxavir marboxil API enriches pipeline but production/sales timing and conditions are uncertain.